Identifying Risk Factors and Outcome for CNS Involvement in AML
- 24 June 2025
- journal article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 25 (10) , e834-e843
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Central Nervous System Prophylaxis and Treatment in Acute LeukemiasCurrent Treatment Options in Oncology, 2022
- Prognostic factors for clinical outcomes of patients with central nervous system leukemiaHematology/Oncology and Stem Cell Therapy, 2021
- Formulas2018
- Factors associated with risk of central nervous system relapse in patients with non‐core binding factor acute myeloid leukemiaAmerican Journal of Hematology, 2017
- Clinical outcome and efficacy of current anti-leukemic therapy for leptomeningeal involvement in acute myeloid leukemiaInternational Journal of Hematology, 2016
- Cytogenetic profile of patients with acute myeloid leukemia and central nervous system diseaseCancer, 2011
- The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: A Children's Oncology Group studyPediatric Blood & Cancer, 2010
- Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: Results from the GET-LALA groupLeukemia Research, 2008
- Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcomeLeukemia Research, 2004
- Central nervous system involvement in acute nonlymphocytic leukemiaThe American Journal of Medicine, 1987